+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Drug Delivery System Market by Therapeutic Application, Delivery Route, Technology, Drug Type, End User, Sales Channel - Global Forecast to 2030- Product Image
Targeted Drug Delivery System Market by Therapeutic Application, Delivery Route, Technology, Drug Type, End User, Sales Channel - Global Forecast to 2030- Product Image
Sale

Targeted Drug Delivery System Market by Therapeutic Application, Delivery Route, Technology, Drug Type, End User, Sales Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5336727
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Targeted Drug Delivery System Market grew from USD 9.61 billion in 2024 to USD 11.41 billion in 2025. It is expected to continue growing at a CAGR of 18.35%, reaching USD 26.43 billion by 2030.

Pioneering Precision: The Rise of Site-Specific Therapeutics

Innovations in targeted drug delivery systems are reshaping healthcare paradigms by enabling therapies to reach specific sites of action with unprecedented precision. This trend heralds a shift away from broad-spectrum treatments toward approaches that minimize systemic exposure and optimize therapeutic efficacy. As clinicians and researchers strive to address complex diseases with greater specificity, targeted platforms have emerged as foundational technologies poised to redefine safety profiles, dosing regimens, and patient quality of life.

The convergence of materials science, molecular biology, and engineering has given rise to a diverse arsenal of delivery vehicles-ranging from nanoscale carriers to antibody-drug conjugates-that can navigate biological barriers and release payloads in response to local stimuli. These advancements are underpinned by a deeper understanding of disease biology and a growing appetite for personalized medicine. Decision-makers are now evaluating how these platforms can reduce adverse effects, improve clinical outcomes, and generate cost efficiencies across the healthcare ecosystem.

Emerging Drivers Shaping the Future of Targeted Delivery

The landscape of targeted drug delivery is undergoing profound shifts driven by breakthroughs in carrier technology, regulatory adaptations, and collaborative innovation models. Recent approvals of novel antibody-drug conjugates have validated the clinical promise of molecularly guided therapies, spurring investment in next-generation nanocarriers and responsive materials. Concurrently, regulatory pathways are evolving to accommodate advanced therapy medicinal products, reducing time to market and encouraging developers to pursue differentiated platforms.

Strategic partnerships between pharmaceutical companies, academic institutions, and technology firms are accelerating translational research, with open-innovation consortia sharing data on formulation stability, scale-up processes, and in vivo performance. This collaborative ethos has fostered a vibrant pipeline of targeted therapies, emphasizing modular architectures that can be adapted to multiple disease indications. As the focus shifts from proof of concept to real-world implementation, stakeholders are prioritizing manufacturability, cost control, and patient-centric design.

Navigating 2025 Tariff Dynamics to Stabilize Supply Chains

The introduction of new tariff measures by the United States in 2025 has imposed additional duties on select raw materials and delivery components, altering the cost dynamics for manufacturers. Import levies on specialty lipids and polymers, critical to liposome and nanoparticle fabrication, have increased the landed cost of these inputs. As a result, production expenses have risen, prompting companies to reassess supply chain strategies and identify alternative sourcing options.

In response, firms have accelerated their efforts to localize component production, forging alliances with domestic suppliers to mitigate duty burdens and ensure uninterrupted manufacturing. Some organizations are exploring in-house synthesis of complex building blocks to bypass external dependencies, while others are renegotiating existing contracts to secure favorable terms. These adjustments are reshaping procurement models and encouraging vertical integration, ultimately influencing pricing, margins, and investment decisions throughout the value chain.

Unveiling Core Drivers Through Multi-Dimensional Segmentation

The market has been dissected across therapeutic application, delivery route, technology, drug type, end user, and sales channels to uncover nuanced performance drivers and unmet needs. Based on therapeutic application, the demand profile spans autoimmune disorders, cardiovascular conditions, central nervous system diseases, oncology, and orthopedic interventions, with oncology receiving deeper analysis through subcategories of breast, colorectal, and lung cancers. From the perspective of delivery route, modalities include inhalation platforms such as dry powder inhalers, metered dose inhalers and nebulizers, alongside intraocular, intravenous, local injection, oral, and transdermal systems. Technological differentiation is evident in antibody-drug conjugates, dendrimers, liposomes, microspheres, and nanoparticles, each offering distinct pharmacokinetic and targeting capabilities.

Further segmentation by drug type distinguishes biologics, nucleic acids, peptides, and small molecules, reflecting the diverse payloads tailored for specific pathophysiology. End users range from ambulatory surgical centers and clinics to hospitals and research institutes, each with varying adoption rates and infrastructure requirements. Sales channels have also been reviewed, covering direct tender engagements, hospital pharmacy distribution, online pharmacy platforms, and retail pharmacy networks. This comprehensive segmentation framework highlights where innovation clusters, where cost pressures concentrate, and where commercialization opportunities are most ripe for strategic investment.

Capitalizing on Regional Diversities for Market Advancement

Regional dynamics are fueling both divergent growth trajectories and shared opportunities across key geographies. In the Americas, robust investment in biotech innovation, coupled with strong reimbursement frameworks, is accelerating the uptake of advanced delivery platforms. Clinical trial activity remains concentrated in the United States, where academic research centers and startup incubators continue to pioneer novel formulations.

In Europe, the Middle East and Africa region, regulatory harmonization efforts and incentives for orphan drug development are fostering adoption of targeted therapies. However, disparities in healthcare infrastructure among countries necessitate tailored commercialization strategies. Stakeholders are collaborating with regional partners to navigate reimbursement complexities and expand access to specialized treatments.

Asia-Pacific is witnessing rapid expansion driven by rising healthcare expenditure, a growing cancer burden, and government initiatives to localize pharmaceutical manufacturing. Emerging markets such as China and India are investing heavily in research facilities and supply chain capabilities, while established markets in Japan and Australia are leading in early adoption of cutting-edge delivery platforms. These varied regional environments require customized market entry and partnership approaches to maximize impact.

Strategic Imperatives Defining Leading Market Players

Industry leadership in targeted delivery is characterized by robust pipelines, strategic alliances, and investments in scale-up infrastructure. Leading players have diversified their portfolios across multiple platform technologies, combining established modalities like liposomal systems with next-generation constructs such as antibody-drug conjugates and dendrimers. Collaborative R&D agreements with biotech innovators and academic institutions are providing early access to cutting-edge science, while downstream partnerships with contract development and manufacturing organizations are expanding production capacity.

Mergers and acquisitions continue to reshape the competitive landscape, enabling established companies to acquire specialized platforms and talent. Simultaneously, agile newcomers are leveraging lean development models and digital tools to accelerate candidate validation. This dynamic ecosystem is driving iterative improvements in targeting efficiency, payload stability, and patient-centric delivery profiles, reinforcing the strategic importance of flexible technology roadmaps and robust intellectual property portfolios.

Actionable Strategies for Driving Market Leadership

Organizations seeking to capitalize on the momentum of targeted delivery systems should prioritize integration of modular platform architectures that enable rapid customization to new indications. Investing in end-to-end manufacturing capabilities-spanning raw material synthesis, formulation, and aseptic fill/finish-will bolster supply chain resilience and cost control. Strategic collaborations with academic centers and contract partners can de-risk early-stage development while facilitating technology transfer and scale-up.

Market entrants and incumbents alike should develop differentiated pricing models that reflect the value proposition of precision therapies, engaging payers early to establish reimbursement pathways. Embracing digital tools for patient monitoring and adherence can enhance real-world evidence generation, supporting broader adoption. Finally, leadership teams must foster cross-functional expertise-combining biology, engineering, regulatory affairs, and commercial strategy-to navigate complex regulatory environments and expedite time to market.

Rigorous Methodology Bolstering Insight Credibility

This analysis is grounded in a systematic review of primary and secondary information. Extensive interviews were conducted with executive-level stakeholders from pharmaceutical firms, academia, and contract service providers to capture firsthand perspectives on development challenges and market priorities. Proprietary data on clinical pipeline activity, regulatory approvals, and patent landscapes were integrated with insights from industry databases to map technology trends and competitive positioning.

Quantitative assessments were performed to evaluate component cost structures, pricing models, and sales channel performance, ensuring that conclusions are supported by robust empirical evidence. Regional case studies were developed through collaboration with local market experts to address nuanced regulatory and infrastructure considerations. All findings were validated via a rigorous review process to ensure accuracy, relevance, and strategic applicability.

Synthesis of Insights into the Future of Precision Therapies

Targeted drug delivery systems stand at the forefront of therapeutic innovation, offering compelling advantages in safety, efficacy, and patient outcomes. The confluence of advanced materials, precision engineering, and regulatory support has established a fertile environment for continuous breakthroughs. While external factors such as tariff policies and regional disparities present challenges, the adaptive strategies adopted by market participants underscore the resilience and growth potential of this sector.

By leveraging multi-dimensional segmentation and region-specific insights, stakeholders can align their R&D investments, manufacturing capabilities, and commercial approaches with evolving demand patterns. As strategic alliances and technology platforms mature, the industry is poised to deliver increasingly personalized treatments that address complex disease landscapes. This report’s analysis provides a foundation for informed decision-making, ensuring that organizations capitalize on emerging opportunities and navigate potential headwinds with confidence.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Application
    • Autoimmune
    • Cardiovascular
    • Central Nervous System
    • Oncology
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
    • Orthopedic
  • Delivery Route
    • Inhalation
      • Dry Powder Inhaler
      • Metered Dose Inhaler
      • Nebulizer
    • Intraocular
    • Intravenous
    • Local Injection
    • Oral
    • Transdermal
  • Technology
    • Antibody Drug Conjugates
    • Dendrimers
    • Liposomes
    • Microspheres
    • Nanoparticles
  • Drug Type
    • Biologics
    • Nucleic Acids
    • Peptides
    • Small Molecule
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Hospitals
    • Research Institutes
  • Sales Channel
    • Direct Tender
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Sanofi S.A.
  • GSK plc
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Targeted Drug Delivery System Market, by Therapeutic Application
8.1. Introduction
8.2. Autoimmune
8.3. Cardiovascular
8.4. Central Nervous System
8.5. Oncology
8.5.1. Breast Cancer
8.5.2. Colorectal Cancer
8.5.3. Lung Cancer
8.6. Orthopedic
9. Targeted Drug Delivery System Market, by Delivery Route
9.1. Introduction
9.2. Inhalation
9.2.1. Dry Powder Inhaler
9.2.2. Metered Dose Inhaler
9.2.3. Nebulizer
9.3. Intraocular
9.4. Intravenous
9.5. Local Injection
9.6. Oral
9.7. Transdermal
10. Targeted Drug Delivery System Market, by Technology
10.1. Introduction
10.2. Antibody Drug Conjugates
10.3. Dendrimers
10.4. Liposomes
10.5. Microspheres
10.6. Nanoparticles
11. Targeted Drug Delivery System Market, by Drug Type
11.1. Introduction
11.2. Biologics
11.3. Nucleic Acids
11.4. Peptides
11.5. Small Molecule
12. Targeted Drug Delivery System Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Clinics
12.4. Hospitals
12.5. Research Institutes
13. Targeted Drug Delivery System Market, by Sales Channel
13.1. Introduction
13.2. Direct Tender
13.3. Hospital Pharmacy
13.4. Online Pharmacy
13.5. Retail Pharmacy
14. Americas Targeted Drug Delivery System Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Targeted Drug Delivery System Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Targeted Drug Delivery System Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Johnson & Johnson
17.3.2. F. Hoffmann-La Roche Ltd
17.3.3. Novartis AG
17.3.4. Pfizer Inc.
17.3.5. Merck & Co., Inc.
17.3.6. AstraZeneca PLC
17.3.7. Sanofi S.A.
17.3.8. GSK plc
17.3.9. AbbVie Inc.
17.3.10. Teva Pharmaceutical Industries Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. TARGETED DRUG DELIVERY SYSTEM MARKET MULTI-CURRENCY
FIGURE 2. TARGETED DRUG DELIVERY SYSTEM MARKET MULTI-LANGUAGE
FIGURE 3. TARGETED DRUG DELIVERY SYSTEM MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. TARGETED DRUG DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. TARGETED DRUG DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TARGETED DRUG DELIVERY SYSTEM MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LOCAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NUCLEIC ACIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 68. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 69. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 70. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 71. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 76. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 78. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. GERMANY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. GERMANY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 117. GERMANY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 118. GERMANY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 119. GERMANY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 120. GERMANY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. GERMANY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. FRANCE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. FRANCE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 125. FRANCE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 126. FRANCE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 127. FRANCE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 128. FRANCE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. FRANCE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. ITALY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. ITALY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 141. ITALY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 142. ITALY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 143. ITALY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. ITALY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. ITALY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. ITALY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. SPAIN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. SPAIN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 149. SPAIN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 150. SPAIN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 151. SPAIN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. SPAIN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 153. SPAIN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. SPAIN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 174. SOUTH AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. DENMARK TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. DENMARK TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 181. DENMARK TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 182. DENMARK TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 183. DENMARK TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 184. DENMARK TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 185. DENMARK TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. DENMARK TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 189. NETHERLANDS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 190. NETHERLANDS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 191. NETHERLANDS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. NETHERLANDS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. QATAR TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. QATAR TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 197. QATAR TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 198. QATAR TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 199. QATAR TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 200. QATAR TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 201. QATAR TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. QATAR TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. FINLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. FINLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 205. FINLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 206. FINLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 207. FINLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. FINLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 209. FINLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. FINLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 221. NIGERIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 222. NIGERIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 223. NIGERIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 224. NIGERIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 225. NIGERIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. NIGERIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. EGYPT TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. EGYPT TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 229. EGYPT TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 230. EGYPT TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 231. EGYPT TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. EGYPT TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 233. EGYPT TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. EGYPT TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. TURKEY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. TURKEY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 237. TURKEY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 238. TURKEY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 239. TURKEY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 240. TURKEY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 241. TURKEY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. TURKEY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. ISRAEL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. NORWAY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. NORWAY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 253. NORWAY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 254. NORWAY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 255. NORWAY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 256. NORWAY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 257. NORWAY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. NORWAY TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. POLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. POLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 261. POLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 262. POLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 263. POLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 264. POLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 265. POLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. POLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. SWITZERLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 269. SWITZERLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 270. SWITZERLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 271. SWITZERLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 272. SWITZERLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 273. SWITZERLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. SWITZERLAND TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 278. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 280. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 284. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 286. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 287. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 288. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 289. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 290. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. INDIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. INDIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 294. INDIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 295. INDIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 296. INDIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 297. INDIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 298. INDIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. INDIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 302. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 303. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 304. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 305. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 306. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 309. AUSTRALIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 310. AUSTRALIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 311. AUSTRALIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 312. AUSTRALIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 313. AUSTRALIA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030

Companies Mentioned

The companies profiled in this Targeted Drug Delivery System market report include:
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Sanofi S.A.
  • GSK plc
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.41 Billion
Forecasted Market Value ( USD ) by 2030 $ 26.43 Billion
Compound Annual Growth Rate18.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Drug Delivery Systems Market by Route of Administration, Technology, Product Type, Application, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Drug Delivery Systems Market by Route of Administration, Technology, Product Type, Application, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Ophthalmic Drug Delivery System Market by Drug Type, Delivery Device Type, Product Type, Formulation Type, Mode Of Delivery, Application, End User - Global Forecast to 2030 - Product Image

Ophthalmic Drug Delivery System Market by Drug Type, Delivery Device Type, Product Type, Formulation Type, Mode Of Delivery, Application, End User - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Novel Drug Delivery Systems (NDDS) - Global Strategic Business Report - Product Image

Novel Drug Delivery Systems (NDDS) - Global Strategic Business Report

  • Report
  • 492 Pages
  • Global
From
Advanced Drug Delivery Systems - A Global Market Overview - Product Image

Advanced Drug Delivery Systems - A Global Market Overview

  • Report
  • 277 Pages
  • Global
From
Targeted Drug Delivery Device Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area, Key Geographical Regions, Leading Players and Sales Forecast - Product Image

Targeted Drug Delivery Device Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area, Key Geographical Regions, Leading Players and Sales Forecast

  • Report
  • 275 Pages
  • Global
From

About the Market

Targeted Drug Delivery System (TDDS) is a specialized area within the broader pharmacological field of Drug Delivery. TDDS aims to direct medication to specific cells, tissues, or organs, thereby increasing the concentration of the drug at the intended site of action while minimizing its presence in the rest of the body. This method potentially reduces side effects and enhances treatment efficacy. The market for these systems encompasses a wide range of technologies and platforms, such as nanoparticles, liposomes, and biodegradable polymers designed to release pharmaceutical compounds in a controlled manner. The field has been propelled by advances in biotechnology, nanotechnology, and molecular biology, which have contributed to the development of novel targeted drug delivery mechanisms. These include antibodies, receptor-mediated delivery systems, and gene-delivery vectors. TDDS is used in addressing various medical conditions, with cancer therapy being a particularly active area due to the need for precise drug delivery to tumor cells. Several companies specialize in the research and development of Targeted Drug Delivery Systems, contributing to the maturation of this market. Some notable players in the field include Alkermes, BIND Therapeutics, DEPArray Technology, Genentech, Immunomedics, Inc., and Kite Pharma. These companies have a diverse product portfolio of targeted delivery technologies and are engaged in the development of innovative treatments for a wide range of diseases, striving to improve therapeutic outcomes and patient quality of life. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.